OS17-02 - 131I-APAMISTAMAB-LED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT DEMONSTRATES SURVIVAL BENEFIT AND OVERCOMES HIGH-RISK TP53 MUTATIONS IN PATIENTS WITH R/R AML

GS02-09 - ADDITION OF NIVOLUMAB TAILORED BY EXPANSION OF CAR-T CELLS IN PATIENTS WITH PROGRESSIVE DLBCL AT LYMPHODEPLETION – A PHASE 2, PROSPECTIVE INTERVENTIONAL STUDY – FINAL ANALYSIS

OS3-06 - CLINICAL EXPERIENCE OF TABELECLEUCEL IN EPSTEIN–BARR VIRUS-POSITIVE POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV+ PTLD) INVOLVING THE CENTRAL NERVOUS SYSTEM

P233 - EFFICACY AND SAFETY OF RECOMBINANT ERWINIA ASPARAGINASE (JZP458) IN ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL): COMPLETE FOLLOW-UP OF THE CHILDREN’S ONCOLOGY GROUP AALL1931 STUDY

A072 - FINAL RESULTS OF PROSPECTIVE CLINICAL TRIAL EVALUATING OUTPATIENT ADMINISTRATION OF AXICABTAGENE CILOLEUCEL IN HIGH-GRADE B CELL LYMPHOMA

OS1-02 - HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS OF OLDER AGE WITH AML IN FIRST COMPLETE REMISSION: RESULTS OF A RANDOMIZED PHASE III TRIAL OF THE EBMT

A101 - LOCOMMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL-LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA – FINAL ANALYSIS AT 2-YEAR FOLLOW-UP

OS10-02 - PHASE 2 CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL IN MULTIPLE MYELOMA AND 1–3 PRIOR LINES (COHORT A) AND WITH EARLY RELAPSE AFTER FRONTLINE TREATMENT (COHORT B)

A108 - PHASE I/II STUDY ON INFUSION OF ALLOREACTIVE OR EX VIVO IL-15 STIMULATED NK CELLS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA